Nurix Therapeutics Financial Statements
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nurix Therapeutics revenue and earnings
In fiscal 2025, Nurix Therapeutics generated $84.0 million in revenue, up 54.0% from fiscal 2024. Nurix Therapeutics reported a net loss of $264.5 million, compared with a loss of $193.6 million a year earlier. Operating margin was -340.2%.
Diluted earnings per share came in at -$3.05. Over the last 5 fiscal years, NRIX's revenue has grown at a 36.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Nurix Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-11-30 | FY 20242024-11-30 | FY 20232023-11-30 | FY 20222022-11-30 | FY 20212021-11-30 | FY 20202020-11-30 | FY 20192019-11-30 |
|---|---|---|---|---|---|---|---|
| Revenue | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M | 17.82M | 31.11M |
| Revenue growth (YoY) | +53.95% | -29.15% | +99.31% | +29.84% | +66.95% | -42.73% | — |
| Operating Expenses | 369.65M | 267.58M | 232.05M | 222.49M | 147.64M | 82.80M | 53.35M |
| Research & Development | 316.90M | 221.63M | 189.15M | 184.50M | 116.43M | 66.49M | 45.02M |
| Operating Income | -285.67M | -213.03M | -155.06M | -183.87M | -117.89M | -64.98M | -22.24M |
| Pretax Income | -263.70M | -193.30M | -143.95M | -180.36M | -117.06M | -63.78M | -21.46M |
| Income Tax | 760.00K | 270.00K | 0 | 0 | 131.00K | -20.54M | 239.00K |
| Net Income | -264.46M | -193.57M | -143.95M | -180.36M | -117.19M | -43.24M | -21.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -6.59 |
| EPS (Diluted) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -6.59 |
| Shares Outstanding (Basic) | 86.67M | 67.12M | 54.34M | 48.61M | 42.90M | 15.67M | 3.29M |
| Shares Outstanding (Diluted) | 86.67M | 67.12M | 54.34M | 48.61M | 42.90M | 15.67M | 3.29M |
| EBITDA | -276.93M | -203.71M | -147.53M | -178.52M | -115.10M | -62.80M | -19.88M |
| Operating Margin | -340.16% | -390.52% | -201.41% | -476.01% | -396.26% | -364.66% | -71.46% |
| Net Margin | -314.90% | -354.85% | -186.98% | -466.93% | -393.93% | -242.66% | -69.74% |
This table shows 7 annual periods of Nurix Therapeutics's income statement, from FY 2025 back to FY 2019, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow NRIX's reporting calendar. What is a income statement?